Drugs that contain Pomalidomide
1. Drug name - POMALYST
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8828427 | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Jun, 2031
(8 years from now) | |
| CN102333525A | CELGENE | Formulation Of 4-Amino-2-(2,6-Dioxopiperidine-3-Yl)Isoindoline-1,3-Dione |
Jan, 2017
(5 years ago) | |
| EP3351240B1 | CELGENE | Formulations Of 4-Amino-2-(2,6-Dioxopiperidine-3-Yl)Isoindoline-1,3-Dione |
May, 2030
(7 years from now) | |
| EP2391355B1 | CELGENE | Formulations Of 4-Amino-2-(2,6-Dioxopiperidine-3-Yl)Isoindoline-1,3-Dione |
May, 2030
(7 years from now) | |
| EP3351240A1 | CELGENE | Formulations Of 4-Amino-2-(2,6-Dioxopiperidine-3-Yl)Isoindoline-1,3-Dione |
May, 2030
(7 years from now) | |
| EP2391355A2 | CELGENE | Formulations Of 4-Amino-2-(2,6-Dioxopiperidine-3-Yl)Isoindoline-1,3-Dione |
May, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8673939 | CELGENE | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May, 2023
(7 months from now) | |
| US8735428 | CELGENE | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May, 2023
(7 months from now) | |
|
US8735428
(Pediatric) | CELGENE | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov, 2023
(1 year, 1 month from now) | |
|
US8673939
(Pediatric) | CELGENE | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov, 2023
(1 year, 1 month from now) | |
| US8198262 | CELGENE | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Jun, 2025
(2 years from now) | |
|
US8198262
(Pediatric) | CELGENE | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Dec, 2025
(3 years from now) | |
| US9993467 | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
May, 2030
(7 years from now) | |
| US10555939 | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
May, 2030
(7 years from now) | |
|
US9993467
(Pediatric) | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Nov, 2030
(8 years from now) | |
|
US10555939
(Pediatric) | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Nov, 2030
(8 years from now) | |
|
US8828427
(Pediatric) | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Dec, 2031
(9 years from now) | |
Treatment: Use of pomalidomide for the treatment of multiple myeloma; use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy; Use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy; use of pomalidomide for the treatment of multiple myeloma
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 1MG | CAPSULE;ORAL | Prescription |
| 2MG | CAPSULE;ORAL | Prescription |
| 3MG | CAPSULE;ORAL | Prescription |
| 4MG | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.